Azithromycin for injection

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (Group A β-hemolytic streptococci), Pneumococcus, α-hemolytic Streptococcus (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including Streptococcus faecalis (Enterococcus) and methicillin-resistant Staphylococcus aureus strains. Gram-negative aerobic bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Acinetobacter, Yersinia, Legionella pneumophila, Bordetella pertussis, Bordetella parapertussis, Shigella, Pasteurella, Vibrio cholerae, Parahaemolyticus, Shigella-like Pseudomonas. The activity of this product against the following Gram-negative bacteria depends on the strain, and sensitivity testing is required: Escherichia coli, Salmonella typhi, Enterobacter, Hydrophila, Klebsiella. Anaerobic bacteria: Bacteroides fragilis, Bacteroides, Clostridium perfringens, Peptostreptococcus, Fusobacterium necroticum, Propionibacterium acnes. Sexually transmitted disease microorganisms: Treponema pallidum, Neisseria gonorrhoeae, Haemophilus dukei. Other microorganisms: including Borrelia tenens (Lyme disease body), Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum, Chlamydia trachomatis, Pneumocystis carinii, Mycobacterium avium, Campylobacter, Listeria monocytogenes. The following Gram-negative bacteria are usually resistant: Proteus, Serratia, Morganella, Pseudomonas. The mechanism of action is the same as erythromycin, mainly binding to the 50S subunit of the bacterial ribosome, inhibiting RNA-dependent protein synthesis.

The main ingredient of this product is azithromycin.

This product is white or off-white loose lumps.

This product is suitable for the following infections caused by sensitive pathogenic strains: 1. Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus or Streptococcus pneumoniae, which requires intravenous drip treatment first. 2. Pelvic inflammatory disease caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma hominis, which requires intravenous drip treatment first.

Dissolve this product in an appropriate amount of water for injection to prepare 0.1g/ml, then add it to 250ml or 500ml of sodium chloride injection or 5% glucose injection. The final azithromycin concentration is 1.0-2.0mg/ml, and then drip it intravenously. The concentration is 1.0mg/ml, and the drip time is 3 hours; the concentration is 2.0mg/ml, and the drip time is 1 hour. 1. Treatment of community-acquired pneumonia: 0.5g for adults once a day, once a day, for at least 2 consecutive days, followed by azithromycin oral preparations 0.5g a day, 7 to 10 days as a course of treatment. The time to switch to oral treatment should be determined by the physician based on the clinical treatment response. 2. Treatment of pelvic inflammatory disease: 0.5g for adults once a day, once a day, after 1 or 2 days of medication, switch to azithromycin oral preparations 0.25g a day, 7 days a course of treatment. The time to switch to oral treatment should be determined by the physician based on the clinical response.

1. Common adverse reactions of this product include: (1) Gastrointestinal reactions: diarrhea, abdominal pain, loose stools, nausea, vomiting, etc. (2) Local reactions: pain at the injection site, local inflammation, etc. (3) Skin reactions: rash, itching. (4) Other reactions: such as loss of appetite, vaginitis, stomatitis, dizziness or dyspnea, etc. 2. This product may also cause the following reactions: (1) Digestive system: indigestion, flatulence, mucositis, oral candidiasis, gastritis, etc. (2) Nervous system: headache, drowsiness, etc. (3) Allergic reactions: bronchospasm, etc. (4) Other reactions: abnormal taste, etc. (5) Laboratory tests: increased serum aminotransferase, creatinine, lactate dehydrogenase, bilirubin and alkaline phosphatase, decreased white blood cell, neutrophil and platelet counts.

It is contraindicated in patients who are allergic to azithromycin, erythromycin, or any other macrolide drugs.

Precautions for children: The safety of this product for patients under 16 years old is not clear. Precautions for pregnancy and lactation: Animal experiments show that this product has no effect on the fetus, but there is still a lack of experience in its use in pregnant women, so the pros and cons must be fully weighed before using it in pregnant women. There is no data to show whether this product can be secreted into breast milk, so the use of this product in lactating women must be considered with caution. Precautions for the elderly:

1. When used in combination with theophylline, the latter's concentration in plasma can be increased, and attention should be paid to detecting plasma theophylline levels. 2. When used in combination with warfarin, attention should be paid to checking the prothrombin time. 3. When used simultaneously with the following drugs, it is recommended to closely observe the patient: Digoxin - increases digoxin levels. Ergotamine or dihydroergotamine - acute ergot toxicity, symptoms are severe peripheral vasospasm and dysesthesia (pain when touching objects). Triazolam - enhances the pharmacological effect of triazolam by reducing the degradation of triazolam. Cytochrome P450 system metabolites - increase the levels of carbamazepine, terfenadine, cyclosporine, cyclohexylbarbital, and phenytoin in serum. 4. When used in combination with rifabutin, the latter's toxicity will be increased.

Keep away from light, tightly closed and in a dry place.

0.25g (250,000 units)

Zhejiang Yatai Pharmaceutical Co., Ltd.

• Founded in:

  2001-12-31

• Address:

  Room 1501, No. 2003, Qunxian Road, Keqiao District, Shaoxing City, Zhejiang Province

• Tax NO.:

  91330000146008822C

• Registered Funds:

  609.17106 million yuan

• Website:

  Log in to view

• Email:

  Log in to view